Literature DB >> 22863163

Cerebrovascular consequences of pseudohyperaldosteronism.

Jonathan H Smith1, Noralane M Lindor, Alejandro A Rabinstein.   

Abstract

The study of mechanistically defined forms of hypertension may provide insight into the relationship between hypertension and stroke. The author retrospectively studied a cohort of 23 individuals with pseudohyperaldosteronism (PHA), a condition associated with pathologic activation of the distal nephron epithelial sodium channel but low renin and aldosterone levels. During a median follow-up of 11 years (range: 1-30), 4 of 23 (17.4%) patients had a cerebrovascular event recorded. Intracranial hemorrhage was not observed in any patient. Cerebrovascular events tended to occur in older patients, minorities, and patients with a later diagnosis of PHA and additional vascular risk factors. In addition to strict blood pressure control, patients with PHA should have early evaluation and treatment of other vascular risk factors to reduce the risk of stroke.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863163      PMCID: PMC8108832          DOI: 10.1111/j.1751-7176.2012.00639.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  26 in total

Review 1.  Liddle syndrome: genetics and mechanisms of Na+ channel defects.

Authors:  D G Warnock
Journal:  Am J Med Sci       Date:  2001-12       Impact factor: 2.378

Review 2.  Blood pressure and stroke: an overview of published reviews.

Authors:  Carlene M M Lawes; Derrick A Bennett; Valery L Feigin; Anthony Rodgers
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

3.  Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study.

Authors:  S Takami; Y Imai; T Katsuya; T Ohkubo; I Tsuji; K Nagai; H Satoh; S Hisamichi; J Higaki; T Ogihara
Journal:  Am J Hypertens       Date:  2000-02       Impact factor: 2.689

4.  Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men.

Authors:  T S Bowman; J M Gaziano; C S Kase; H D Sesso; T Kurth
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

5.  Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism.

Authors:  W R Litchfield; B F Anderson; R J Weiss; R P Lifton; R G Dluhy
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study.

Authors:  W B Kannel; P A Wolf; D L McGee; T R Dawber; P McNamara; W P Castelli
Journal:  JAMA       Date:  1981-03-27       Impact factor: 56.272

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.